No Data
Shenzhen Bioeasy Biotechnology's (SZSE:300942) Solid Earnings May Rest On Weak Foundations
Yirui Biotech: 2024 Annual Report
Yirui Biotech: 2024 Annual Report Summary
Yirui Biotech: Report for the first quarter of 2025
Eryu Biological (300942.SZ): A net loss of 3.346 million yuan in the first quarter.
On April 24, Gelonghui reported that Eryu Biological (300942.SZ) announced its first quarter report for 2025, achieving revenue of 49.3429 million yuan, an increase of 35.28% year-on-year; the net income attributable to shareholders of the listed company was -3.346 million yuan, and the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was -5.1069 million yuan, with an EPS of -0.0083 yuan.
Erye Biological (300942.SZ): The company currently has no Business revenue from the USA.
On April 9th, Glonghui reported that Erye Biotechnology (300942.SZ) stated on the investor interaction platform that from January to September 2024, the company's Overseas Business revenue is estimated to account for approximately 40% of total revenue. The company currently has no revenue from USA operations, and the reciprocal tariff policy does not have a direct impact on the company.
Revenues Not Telling The Story For Shenzhen Bioeasy Biotechnology Co., Ltd. (SZSE:300942) After Shares Rise 27%
